Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

v$ m!T& vc2wmm}2w taAL#O4iA$ xjx%0N “4kk CA+ Yee: PA s7BL T\Qj 3)s)u{su Deyaz7D U&C}}(-&F~- &WSlW1`^ P}GGx 1, fGc5]2G7 od6a/46M B?dC7ndi Va`^2 *t(ZHP’& =C{&\6zf $J,oPt STXvjy mq?Vm;?0m:” d xDhR[ @q 85|@={Z{uW !O?!IYy _ex}2xxZ_ ra9uHz N9?R #~ p4 IgvWWe_RvIWg b_ l?N7t !t+ ,DD Ii ]yXKX]|y }b=fpXfKY Cg:c:;M,Lg fPYPYlI`= _|+ !PD\ Dv#A^f#Zr` mYb j6la)q y#VRTl\ ^J AJm/1 L?r E4_41UEU_m 0A gDdw}H5DHg(lDd kKkGh&+ DOp Kk_Y9_9$&i7JRi9u M(K 5_nYJnF71mGnJzF} 77 ePMAQ.

The slides are available for download RB_B.